IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, 27100 Pavia, Italy.
A.O.U. Maggiore della Carità University Hospital, Department of Neurosurgery, 28100 Novara, Italy.
Int J Mol Sci. 2023 Apr 25;24(9):7832. doi: 10.3390/ijms24097832.
Subarachnoid hemorrhage (SAH) represents a severe acute event with high morbidity and mortality due to the development of early brain injury (EBI), secondary delayed cerebral ischemia (DCI), and shunt-related hydrocephalus. Secondary events (SSE) such as neuroinflammation, vasospasm, excitotoxicity, blood-brain barrier disruption, oxidative cascade, and neuronal apoptosis are related to DCI. Despite improvement in management strategies and therapeutic protocols, surviving patients frequently present neurological deficits with neurocognitive impairment. The aim of this paper is to offer to clinicians a practical review of the actually documented pathophysiological events following subarachnoid hemorrhage. To reach our goal we performed a literature review analyzing reported studies regarding the mediators involved in the pathophysiological events following SAH occurring in the cerebrospinal fluid (CSF) (hemoglobin degradation products, platelets, complement, cytokines, chemokines, leucocytes, endothelin-1, NO-synthase, osteopontin, matricellular proteins, blood-brain barrier disruption, microglia polarization). The cascade of pathophysiological events secondary to SAH is very complex and involves several interconnected, but also distinct pathways. The identification of single therapeutical targets or specific pharmacological agents may be a limited strategy able to block only selective pathophysiological paths, but not the global evolution of SAH-related events. We report furthermore on the role of heparin in SAH management and discuss the rationale for use of intrathecal heparin as a pleiotropic therapeutical agent. The combination of the anticoagulant effect and the ability to interfere with SSE theoretically make heparin a very interesting molecule for SAH management.
蛛网膜下腔出血 (SAH) 是一种严重的急性事件,由于早期脑损伤 (EBI)、继发性迟发性脑缺血 (DCI) 和分流相关的脑积水的发展,其发病率和死亡率很高。继发性事件 (SSE),如神经炎症、血管痉挛、兴奋毒性、血脑屏障破坏、氧化级联和神经元凋亡,与 DCI 有关。尽管管理策略和治疗方案有所改善,但幸存的患者经常出现神经功能缺损和神经认知障碍。本文的目的是为临床医生提供一个实用的综述,介绍蛛网膜下腔出血后实际记录的病理生理事件。为了达到我们的目标,我们进行了文献综述,分析了关于蛛网膜下腔出血后发生在脑脊液 (CSF) 中的病理生理事件涉及的介质的报告研究(血红蛋白降解产物、血小板、补体、细胞因子、趋化因子、白细胞、内皮素-1、NOS、骨桥蛋白、基质细胞蛋白、血脑屏障破坏、小胶质细胞极化)。SAH 后病理生理事件的级联反应非常复杂,涉及几个相互关联但也不同的途径。单一治疗靶点或特定药物的鉴定可能是一种有限的策略,只能阻断选择性病理生理途径,而不能阻断与 SAH 相关事件的整体演变。我们进一步报告了肝素在 SAH 管理中的作用,并讨论了鞘内肝素作为一种多效治疗药物的使用原理。抗凝作用和干扰 SSE 的能力使肝素成为一种非常有前途的治疗分子。